Additional non-invasive options can be considered for erectile dysfunction when phosphodiesterase type 5 inhibitors fail

2018 ◽  
Vol 34 (12) ◽  
pp. 567-571
Author(s):  
Keyword(s):  
Erectile Dysfunction ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Non Invasive ◽  
Phosphodiesterase Type

scholarly journals Efficacy of Intracavernosal Injections of 50-Unit versus 100-Unit Doses of AbobotulinumtoxinA (Masport®) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant

2022 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Sajad Moradi ◽  
Dinyar Khazaeli ◽  
Mohammadreza Dadfar ◽  
Nima Bakhtiari
Keyword(s):  
Erectile Dysfunction ◽  
Single Dose ◽  
Unit Group ◽  
P Value ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Systemic Complications ◽  
Significant Difference ◽  
Unit Dose ◽  
Phosphodiesterase Type ◽  
Intracavernosal Injections

Background: We aimed to evaluate the safety and efficacy of 50-unit dose against 100-unit dose of intracavernosal injection (ICI) of AbobotulinumtoxinA (BTX-A) (Masport®) in patients with vascular erectile dysfunction (ED) resistant to first-line therapies, including phosphodiesterase type 5 inhibitors (PDE5I). Methods: In this double-blind randomized controlled trial (RCT), 40 patients with ED resistant to PDE5I were randomly divided into two groups: ICI of a single dose of Masport® 50 units and single dose of 100 units. Peak systolic velocity (PSV) confirmed arterial insufficiency vascular disorder. For all patients, IIEF (International Index of Erectile Function), SHIM (Sexual Health Inventory for Men), and EHS (Erection Hardness Score) questionnaires were completed. Six weeks after the treatment, the subjects were re-examined. Results: Our results showed an acceptable clinical efficacy and safety of ICI of Masport® six weeks after injection. No systemic complications in patients were seen. Three patients complained of brief penile pain shortly after injection, but there were no other local complications. The increase in mean PSV in the 100-unit group due to treatment was significant (P-value < 0.0001). Also, there was a significant difference between the two groups of 50- and 100-unit (P-value < 0.0001). In addition, the increase in mean IIEF-EF, SHIM score, and EHS due to treatment was significant between the two groups. For the 100-unit group, P-value < 0.0001 and the difference between the two groups was also significant (P-value < 0.0001), which indicated a better response to treatment in the 100-unit group. The mean increase of IIEF score (EF domain) was 4.3 (mean IIEF: 9.4 and 13.7 after and before, respectively) in the 100-unit group and (mean IIEF: 8.1 and 9.1 after and before, respectively) in the 50-unit group. Conclusions: The results of this study showed that ICI of AbobotulinumtoxinA, especially at a dose of 100 units, in patients with refractory vasculogenic ED is safe and effective in improving sexual function and ultrasound indices.

scholarly journals Peculiarities of correction of sexual function in men presenting with diabetes mellitus

2010 ◽  
Vol 13 (3) ◽  
pp. 30-31
Author(s):  
Roman Viktorovich Rozhivanov ◽  
Alexander Evgen'evich Lepetukhin ◽  
Sergey Anatol'evich Dubskiy ◽  
Dmitriy Gennad'evich Kurbatov
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Sexual Function ◽  
Lipoic Acid ◽  
Research Centre ◽  
Alpha Lipoic Acid ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Phosphodiesterase Type

Diabetes mellitus (DM) is frequently associated with disturbances of the sexual function underlain by hypogonadism and neuropathy. These pathologicalconditions are successfully managed by androgens, alpha-lipoic acid, and phosphodiesterase type 5 inhibitors, besides compensation of carbohydratemetabolism. This paper reports results of evaluation of different methods for the treatment of erectile dysfunction in DM patients basedat Endocrinological Research Centre. Their combination ensured higher than 90% efficiency of therapy.

Drugs

ESC CardioMed ◽  
2018 ◽  
pp. 1030-1035
Author(s):  
Mike Kirby ◽  
Jonny Coxon
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Negative Effects ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Cardiac Condition ◽  
Male Patients ◽  
Phosphodiesterase Type ◽  
The Impact

It should not be presumed that male patients with cardiovascular disease are less sexually active than others, but they are more likely to have erectile dysfunction. It is therefore crucial to consider the impact on sexual function of medications commonly used to treat cardiovascular disease, because negative effects on erectile dysfunction can lead to problems with compliance and quality of life. Cardiovascular implications of phosphodiesterase type 5 inhibitors used to treat erectile dysfunction should be borne in mind. Effective treatment of the cardiac condition should always take priority.

Impact of undiagnosed prediabetes on phosphodiesterase type 5 inhibitors response in men with erectile dysfunction

2019 ◽  
Vol 18 (9) ◽  
pp. e3216-e3217
Author(s):  
L. Boeri ◽  
P. Capogrosso ◽  
E. Ventimiglia ◽  
W. Cazzaniga ◽  
E. Pozzi ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Phosphodiesterase Type

Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction

2005 ◽  
Vol 23 (6) ◽  
pp. 374-384 ◽  
Author(s):  
Alberto Briganti ◽  
Andrea Salonia ◽  
Federico Deho’ ◽  
Giuseppe Zanni ◽  
Luigi Barbieri ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Phosphodiesterase Type
Sign in / Sign up

Export Citation Format

Share Document